The Role of Functional Neuroimaging in Mild Cognitive Impairment

Marcos, Alberto; Barabash, Ana; Gil, Pedro; Encinas, Marta; De Juan, Ramón; Payno, María; Ancín, Inés; Vázquez, Blanca; Antonio Cabranes, José
June 2006
Current Medical Imaging Reviews;2006, Vol. 2 Issue 2, p237
Academic Journal
Mild Cognitive impairment (MCI) is a frequent problem in the elderly, since many of MCI subjects progress into Alzheimer's disease (AD). Recently new treatment options have been developed that may alter or delay the rate of AD deterioration. Wherefore, detecting and recognising patients that have a higher risk of developing dementia allows for the planning of correct treatments, future care and research purposes. Although there are no markers that certainly predict the progression to dementia, some useful clinical or biological features have been reported. A reduced perfusion, glucose metabolism or atrophy in local areas of the cerebral cortex assessed by functional or conventional imaging technics, some genes, CSF proteins and psychological test, have been described as risk factors for the development of AD. Even if there is not one single diagnostic method with enough sensibility or specificity to allow a sure outcome, combining early clinical, regional cerebral blood flow and genetics markers we can improve accuracy on predicting the progression from MCI to AD. We review the clinical diagnostic criteria of MCI, the increasing literature about its diagnosis, and we describe the recent findings under the light of our experience following up patients during 5 years.


Related Articles

  • Clinical Features of Mild Cognitive Impairment Differ in the Research and Tertiary Clinic Settings. Jicha, G. A.; Abner, E.; Schmitt, F. A.; Cooper, G. E.; Stiles, N.; Hamon, R.; Carr, S.; Smith, C. D.; Markesbery, W. R. // Dementia & Geriatric Cognitive Disorders;2008, Vol. 26 Issue 2, p187 

    Objective: Comparative analysis of subjects with mild cognitive impairment (MCI) diagnosed in a primary research setting and those seen in a tertiary care memory disorders clinic. Methods: Subjects who received a diagnosis of MCI between July 1, 2005, and December 31, 2006, in a longitudinal...

  • Characterization of Everyday Functioning in Mild Cognitive Impairment: A Direct Assessment Approach. Giovannetti, Tania; Bettcher, Brianne Magouirk; Brennan, Laura; Libon, David J.; Burke, Marykate; Duey, Katia; Nieves, Christine; Wambach, Denene // Dementia & Geriatric Cognitive Disorders;2008, Vol. 25 Issue 4, p359 

    Aims: To evaluate the degree and pattern of functional difficulties in mild cognitive impairment (MCI) via direct observation of everyday task performance. Methods: MCI (n = 25), mild Alzheimer’s disease (AD; n = 25), and control (n = 18) participants performed three everyday tasks of...

  • Changes in Cortical Activation during Retrieval of Clock Time Representations in Patients with Mild Cognitive Impairment and Early Alzheimer’s Disease. Leyhe, Thomas; Erb, Michael; Milian, Monika; Eschweiler, Gerhard W.; Ethofer, Thomas; Grodd, Wolfgang; Saur, Ralf // Dementia & Geriatric Cognitive Disorders;2009, Vol. 27 Issue 2, p117 

    Objective: We investigated healthy controls (HCs), and patients with mild cognitive impairment (MCI) and early Alzheimer’s disease (AD) to identify neuronal correlates of clock time representation and changes resulting from neurodegenerative processes using functional magnetic resonance...

  • Brain SPECT in subtypes of mild cognitive impairment. Nobili, Flavio; Frisoni, Giovanni; Portet, Florence; Verhey, Frans; Rodriguez, Guido; Caroli, Anna; Touchon, Jacques; Calvini, Piero; Morbelli, Silvia; Carli, Fabrizio; Guerra, Ugo; Pol, Laura; Visser, Pieter-Jelle // Journal of Neurology;Sep2008, Vol. 255 Issue 9, p1344 

    The Development of Screening Guidelines and Clinical Criteria of Predementia Alzheimer’s Disease (DESCRIPA) multicenter study enrolled patients with MCI or subjective cognitive complaints (SUBJ), a part of whom underwent optional brain perfusion SPECT. These patients were classified as...

  • Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. Straaten, E.; Harvey, D.; Scheltens, P.; Barkhof, F.; Petersen, R.; Thal, L.; Jack, C.; DeCarli, C. // Journal of Neurology;Sep2008, Vol. 255 Issue 9, p1302 

    White matter hyperintensities (WMH) have an effect on cognition and are increased in severity among individuals with amnestic mild cognitive impairment (aMCI). The influence of WMH on progression of aMCI to Alzheimer’s disease (AD) is less clear. Data were drawn from a three-year...

  • Mild cognitive impairment in different functional domains and incident Alzheimer's disease. Aggarwal, N. T.; Wilson, R. S.; Beck, T. L.; Bienias, J. L.; Bennett, D. A. // Journal of Neurology, Neurosurgery & Psychiatry;Nov2005, Vol. 76 Issue 11, p1479 

    Background: Little is known about factors that predict transition from mild cognitive impairment to Alzheimer's disease (AD).Objective: To examine the relation of impairment in different cognitive systems to risk of developing AD in persons with mild cognitive...

  • Alzheimer's disease, Alzheimer disease.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p87 

    An encyclopedia entry for "Alzheimer's disease" which refers to a degenerative cognitive disorder is presented.

  • Genetics, Alzheimer's disease and senile dementia. Kay, D. W. K.; Kay, D W // British Journal of Psychiatry;Mar89, Vol. 154, p311 

    Genetic factors in the aetiology of Alzheimer's disease (AD), are now being intensively investigated. The homogeneity of AD is under investigation. There are a few large kindreds with early onset of AD in whom transmission appears to be typically autosomal dominant, and 65% or more of the...

  • Neuroprotective Mechanisms as Treatment Strategy in Alzheimer's disease. Nordberg, A. // Current Medicinal Chemistry - Central Nervous System Agents;Nov2001, Vol. 1 Issue 3, p239 

    Alzheimer's disease is the most common dementia disorder characterised by a progressive loss of cognitive function. The major neuropathological hallmark for the disease is the presence of beta amyoloid (A�) in the brain. The research to date indicates there are multiple factors that can...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics